MIRM

Company Overview — What Does Mirum Pharmaceuticals, Inc. Do?

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California. Mirum Pharmaceuticals, Inc. (MIRM) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Christopher Peetz and employs approximately 140 people. With a market capitalization of $5.7B, MIRM is one of the notable companies in the Healthcare sector.

Mirum Pharmaceuticals, Inc. (MIRM) Stock Rating — Reduce (April 2026)

As of April 2026, Mirum Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 41.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MIRM ranks #2,424 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Mirum Pharmaceuticals, Inc. ranks #299 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MIRM Stock Price and 52-Week Range

Mirum Pharmaceuticals, Inc. (MIRM) currently trades at $94.45. The stock lost $4.50 (4.5%) in the most recent trading session. The 52-week high for MIRM is $109.28, which means the stock is currently trading -13.6% from its annual peak. The 52-week low is $36.88, putting the stock 156.1% above its annual trough. Recent trading volume was 723K shares, suggesting relatively thin trading activity.

Is MIRM Overvalued or Undervalued? — Valuation Analysis

Mirum Pharmaceuticals, Inc. (MIRM) carries a value factor score of 36/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 316.95x, compared to the Healthcare sector average of 23.63x — a premium of 1241%. The price-to-book ratio stands at 18.34x, versus the sector average of 2.75x. The price-to-sales ratio is 12.47x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, MIRM trades at 96.89x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Mirum Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Mirum Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Mirum Pharmaceuticals, Inc. (MIRM) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -10.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.8% versus the sector average of -33.1%.

On a margin basis, Mirum Pharmaceuticals, Inc. reports gross margins of 80.8%, compared to 71.5% for the sector. The operating margin is -7.4% (sector: -66.1%). Net profit margin stands at -7.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 70.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MIRM Debt, Balance Sheet, and Financial Health

Mirum Pharmaceuticals, Inc. has a debt-to-equity ratio of 168.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.67x, indicating strong short-term liquidity. Total debt on the balance sheet is $310M. Cash and equivalents stand at $282M.

MIRM has a beta of 0.71, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Mirum Pharmaceuticals, Inc. is 63/100, reflecting average volatility within the normal range for its sector.

Mirum Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Mirum Pharmaceuticals, Inc. reported revenue of $463M and earnings per share (EPS) of $-0.47. Net income for the quarter was $-32M. Gross margin was 80.8%. Operating income came in at $-30M.

In FY 2025, Mirum Pharmaceuticals, Inc. reported revenue of $521M and earnings per share (EPS) of $-0.47. Net income for the quarter was $-23M. Revenue grew 54.7% year-over-year compared to FY 2024. Operating income came in at $-22M.

In Q3 2025, Mirum Pharmaceuticals, Inc. reported revenue of $133M and earnings per share (EPS) of $0.06. Net income for the quarter was $3M. Revenue grew 47.2% year-over-year compared to Q3 2024. Operating income came in at $3M.

In Q2 2025, Mirum Pharmaceuticals, Inc. reported revenue of $128M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-6M. Revenue grew 64.1% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, Mirum Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $78M to $463M. Investors analyzing MIRM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MIRM Dividend Yield and Income Analysis

Mirum Pharmaceuticals, Inc. (MIRM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MIRM Momentum and Technical Analysis Profile

Mirum Pharmaceuticals, Inc. (MIRM) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

MIRM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Mirum Pharmaceuticals, Inc. (MIRM) ranks #299 out of 838 stocks based on the Blank Capital composite score. This places MIRM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MIRM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MIRM vs S&P 500 (SPY) comparison to assess how Mirum Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

MIRM Next Earnings Date

No upcoming earnings date has been announced for Mirum Pharmaceuticals, Inc. (MIRM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MIRM? — Investment Thesis Summary

The quantitative profile for Mirum Pharmaceuticals, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 36/100 indicates premium valuation. Price momentum is positive at 70/100, suggesting the trend favors buyers. Low volatility (stability score 63/100) reduces downside risk.

In summary, Mirum Pharmaceuticals, Inc. (MIRM) earns a Reduce rating with a composite score of 41.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MIRM stock.

Related Resources for MIRM Investors

Explore more research and tools: MIRM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MIRM head-to-head with peers: MIRM vs AZN, MIRM vs SLGL, MIRM vs VMD.